New more effective antimicrobials might rise from old

October 7, 2013, University of California - San Diego
New more effective antimicrobials might rise from old
This is a false-color scanning electron micrograph of the water-borne intestinal parasite Giardia lamblia. Credit: Centers for Disease Control and Prevention

By tinkering with their chemical structures, researchers at the University of California, San Diego School of Medicine have essentially re-invented a class of popular antimicrobial drugs, restoring and in some cases, expanding or improving, their effectiveness against drug-resistant pathogens in animal models.

Writing in the October 7 Early Edition of PNAS, Lars Eckmann, MD, professor of medicine, and colleagues describe creating more than 650 new compounds by slightly altering structural elements of metronidazole and other 5-nitromidazoles (5-NI), a half-century-old class of used to combat everything from an ulcer-causing stomach bacterium to a gut-churning protozoan found in contaminated water.

"The basic building blocks of 5-NI drugs are the same for all. We decorated around them, adding extra molecular pieces to change their shapes and sizes," said Eckmann, who published the paper with colleagues at UC San Diego, The Scripps Research Institute and the Queensland Institute of Medical Research in Australia. The result: The altered shapes changed how many of the new compounds attacked pathogens in animal models, overcoming previous microbial resistance.

The findings could have major ramifications in the on-going struggle against evolving resistance by many disease-causing pathogens. The Centers for Disease Control and Prevention recently estimated at least 2 million Americans fall ill to antibiotic-resistant bacteria each year, with at least 23,000 dying as a direct result of those infections. The World Health Organization (WHO) deems antimicrobial resistance to be an escalating global threat to public health.

"Antibiotic resistance is rising for many different pathogens that are threats to health," said CDC director Tom Frieden, MD, MPH. "If we don't act now, our medicine cabinet will be empty and we won't have the antibiotics we need to save lives."

To be sure, antibiotic varies. "It spans the spectrum," said Eckmann. "We have some disease-causing bugs where the situation is critical, where we're really at risk of losing the ability to treat any . At the other end, some infections are not much impacted at all. It depends upon the particular bug."

The to current 5-NI drugs is equally varied. For example, metronidazole, which is used to treat a wide range of bacterial and parasitic infections, is highly effective against the parasitic protozoan Entamoeba histolytica, which can cause life-threatening gut and liver infections. For Trichomonas vaginalis, a sexually transmitted parasite that infects more Americans than any other eukaryotic pathogen, and Giardia lamblia, a water-borne pathogen that causes diarrheal disease, resistance-linked treatment failure occurs in up to 20 percent of cases. And in some developing countries, more than half of all infections with Helicobacter pylori, a stomach bacterium that causes ulcers and cancer, are resistant to metronidazole.

Eckmann and colleagues say the full antimicrobial potential of 5-NI drugs is not known because efforts to continue commercial development stalled after their introduction in 1960, due in part to unfounded fears they might be mutagenic or increase the frequency of genetic mutations. Subsequent clinical studies have shown 5-NI compounds are safe, with no relevant long-term toxicity in humans.

The challenge now is to re-new interest and investment in the amended drugs. Eckmann would like to further refine them in preparation for eventual human clinical trials. It will be an uphill struggle, he said. While the WHO has classified metronidazole as an "essential medicine," it's no guarantee of a future, lucrative market for any new and approved drugs.

"Pharmaceutical companies are generally reluctant to pursue new drugs unless there's a real market for it," said Eckmann. "They ask themselves, 'Does the drug treat a disease at costs that justify the initial financial investments into drug development?'"

Thanks to their enormous versatility, he is hopeful the answer will be yes for the revamped 5-NI drugs. "These drugs have half-a-dozen or more human targets," he said. "Treating Giardia might not be a major clinical challenge, at least in the United States, but 5-nitro antimicrobials also treat Clostridium difficile."

As its name implies, C. difficile is indeed problematic. The bacterium causes symptoms ranging from diarrhea to life-threatening inflammation of the colon. An estimated half-million Americans get sick each year from C. difficile infections, which are becoming more frequent, severe and hard-to-treat as the bacterium grows increasingly resistant to and other antibiotic therapies. Eckmann said new therapeutic options against this difficult-to-treat infection may find broader commercial interests.

Explore further: 3Qs: The effect of antibiotic resistant bacteria

More information: Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity,

Related Stories

3Qs: The effect of antibiotic resistant bacteria

October 2, 2013
Last month, the Centers for Disease Control and Prevention released a report titled Antibiotic resistance threats in the United States, 2013, that served as a first-ever snapshot of the effect antibiotic resistant microbes ...

When bacteria fight back

September 23, 2013
The U.S. Centers for Disease Control and Prevention (CDC) has issued a report about the growth of drug-resistant bacteria in this country, saying that each year more than 23,000 people die and 2 million are sickened by infections ...

CDC sounds alarm on antibiotic-resistant bacteria

September 16, 2013
(HealthDay)—More than 2 million people come down with infections from antibiotic-resistant bacteria every year in the United States, leading to at least 23,000 deaths, according to a report released Monday by federal health ...

Survey shows increase in resistance to drug therapies among bovine respiratory disease cases

July 1, 2013
A survey of records of bovine respiratory disease cases at the Kansas State Veterinary Diagnostic Laboratory showed that drug resistance in one of the primary pathogens that cause BRD, Mannheimia haemolytica, increased over ...

Bacterial 'autopsy' could speed antibiotic discovery: study

September 20, 2013
(HealthDay)—Scientists say they've found a quicker way to analyze chemicals with bacteria-killing abilities in an advance they hope will speed the development of new antibiotics.

'Cycling' antibiotics might help combat resistance, study suggests

September 26, 2013
(HealthDay)—Doctors might be able to overcome antibiotic-resistant bacteria by swapping out the antibiotics used to treat a patient, providing a "one-two" punch that keeps the germs reeling, a new Danish study suggests.

Recommended for you

Researchers illustrate how muscle growth inhibitor is activated, could aid in treating ALS

January 19, 2018
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for ...

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.